Recent developments in immunotherapy of acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International PublicationsHyperthermia enhances bortezomib-induced apoptosis in human white blood cancer cells
/in Acute Leukemia, Hyperthermia, International PublicationsImmune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia
/in Acute Leukemia, Dendritic Cells, International PublicationsIndividualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
/in Acute Leukemia, Dendritic Cells, International PublicationsInduction of Immune Response after Allogeneic Wilms‘ Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse
/in Acute Leukemia, Dendritic Cells, International PublicationsProgress of dendritic cell-based cancer vaccines for patients with hematological malignancies
/in Acute Leukemia, Chronic Leukemia, Dendritic Cells, International PublicationsLong-term follow-up of patients with acute myelogenous leukemia receiving an autologous telomerase-based dendritic cell vaccine.
/in Acute Leukemia, Dendritic Cells, International PublicationsClinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study
/in Acute Leukemia, Chronic Leukemia, Dendritic Cells, International Publications, Malignant LymphomaClinical trials of dendritic cell-based cancer vaccines in hematologic malignancies
/in Acute Leukemia, Dendritic Cells, International Publications, Multiple Myeloma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer